Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking
NCT ID: NCT00282984
Last Updated: 2017-04-05
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
714 participants
INTERVENTIONAL
2006-02-28
2008-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Safety and Efficacy of Varenicline in Patients That Wish to Stop Smoking
NCT00594204
A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline
NCT00143299
A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation
NCT00141206
A Multi-National Study To Assess How Effective And Safe The Smoking Cessation Medicine Varenicline Is In Smokers Who Have Already Tried Varenicline In The Past As A Prescription Medicine From Their Usual Healthcare Provider
NCT01244061
A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation
NCT00143364
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
placebo
placebo
1 mg placebo twice daily by mouth for 12 weeks
varenicline
Varenicline
1 mg twice daily by mouth for 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
placebo
1 mg placebo twice daily by mouth for 12 weeks
Varenicline
1 mg twice daily by mouth for 12 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants that smoke \> 10 cigarettes / day.
Exclusion Criteria
* Cardiovascular events in the past 2 months
* Moderate or severe chronic obstructive pulmonary disease (COPD)
35 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Hartford, Connecticut, United States
Pfizer Investigational Site
Boston, Massachusetts, United States
Pfizer Investigational Site
Madison, Wisconsin, United States
Pfizer Investigational Site
Capital Federal, Buenos Aires, Argentina
Pfizer Investigational Site
Ciudad de Buenos Aires, Buenos Aires, Argentina
Pfizer Investigational Site
Concord, New South Wales, Australia
Pfizer Investigational Site
Herston, Queensland, Australia
Pfizer Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
Pfizer Investigational Site
São Paulo, São Paulo, Brazil
Pfizer Investigational Site
London, Ontario, Canada
Pfizer Investigational Site
Ottawa, Ontario, Canada
Pfizer Investigational Site
Drummondville, Quebec, Canada
Pfizer Investigational Site
Québec, Quebec, Canada
Pfizer Investigational Site
Brno, , Czechia
Pfizer Investigational Site
Prague, , Czechia
Pfizer Investigational Site
Aarhus C, , Denmark
Pfizer Investigational Site
Hellerup, , Denmark
Pfizer Investigational Site
Caen, , France
Pfizer Investigational Site
Marseille, , France
Pfizer Investigational Site
Toulouse, , France
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Göttingen, , Germany
Pfizer Investigational Site
Tübingen, , Germany
Pfizer Investigational Site
Athens, , Greece
Pfizer Investigational Site
Pireaus, , Greece
Pfizer Investigational Site
Tlalpan, Mexico City, Mexico
Pfizer Investigational Site
Monterrey, Nuevo León, Mexico
Pfizer Investigational Site
Amsterdam, , Netherlands
Pfizer Investigational Site
Zuthpen, , Netherlands
Pfizer Investigational Site
Seoul, Korea, South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Taipei, Taiwan, Taiwan
Pfizer Investigational Site
Tau-Yuan Hsien, , Taiwan
Pfizer Investigational Site
Carshalton, Surrey, United Kingdom
Pfizer Investigational Site
Bradford, West Yorkshire, United Kingdom
Pfizer Investigational Site
Leicester, , United Kingdom
Pfizer Investigational Site
Paisley, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Livingstone-Banks J, Fanshawe TR, Thomas KH, Theodoulou A, Hajizadeh A, Hartman L, Lindson N. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2023 May 5;5(5):CD006103. doi: 10.1002/14651858.CD006103.pub8.
Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010 Jan 19;121(2):221-9. doi: 10.1161/CIRCULATIONAHA.109.869008. Epub 2010 Jan 4.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A3051049
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.